Serum protein-based nanoparticles for cancer diagnosis and treatment
Serum protein-based nanoparticles for cancer diagnosis and treatment
复制标题
用于癌症诊断和治疗的基于血清蛋白的纳米颗粒。
DOI：
10.1016/j.jconrel.2020.10.030
复制
发表时间：
2021-02-20
影响因子：
10.8
通讯作者：
Chen, Huabing
中科院分区：
文献类型：
--
作者：
Iqbal, Haroon;Yang, Tao;Chen, Huabing
血清蛋白作为天然必需的生物大分子，近年来以其优异的生物相容性、良好的药代动力学和增强的靶向能力成为癌症诊断和治疗药物输送的通用载体。目前已有多种血清蛋白用于药物传递，主要包括白蛋白、铁蛋白/载脂蛋白、转铁蛋白、低密度脂蛋白、高密度脂蛋白和血红蛋白。紫杉醇结合白蛋白纳米粒(Abraxane(TM))的成功应用证明，基于血清蛋白的纳米粒在精确的生物学设计和潜在的临床应用方面受到了极大的关注。本文综述了血清蛋白纳米粒在肿瘤纳米医学领域的一般设计策略、靶向机制及最新研究进展。此外，我们还简要说明了目前需要解决的挑战，以期有一个光明的未来的血清蛋白为基础的纳米药物。
Serum protein as naturally essential biomacromolecules has recently emerged as a versatile carrier for diagnostic and therapeutic drug delivery for cancer nanomedicine with superior biocompatibility, improved pharmacokinetics and enhanced targeting capacity. A variety of serum proteins have been utilized for drug delivery, mainly including albumin, ferritin/apoferritin, transferrin, low-density lipoprotein, high-density lipoprotein and hemoglobin. As evidenced by the success of paclitaxel-bound albumin nanoparticles (Abraxane (TM)), serum protein-based nanoparticles have gained attractive attentions for precise biological design and potential clinical application. In this review, we summarize the general design strategies, targeting mechanisms and recent development of serum protein-based nanoparticles in the field of cancer nanomedicine. Moreover, we also concisely specify the current challenges to be addressed for a bright future of serum protein-based nanomedicines.